New Alzheimer's Biomarker Test Developed
Researchers created a highly sensitive plasma test that runs on standard lab equipment to aid in Alzheimer's detection.
Updated on Oct. 7, 2026 in Alzheimer’s
Live Poll
Should medical research focus on simplifying diagnostic tools for use in standard local labs?
Scientists have developed a new platform called SPLASH that quantifies five key Alzheimer's biomarkers using standard laboratory qPCR equipment. This development aims to simplify screening by removing the need for highly specialized instrumentation or centralized infrastructure.
Why it matters
By enabling the use of common benchtop hardware, this approach could significantly improve access to Alzheimer's diagnostic testing. It also allows for the analysis of dried plasma spots without cold-chain storage, which may streamline clinical workflows.
This study tested the SPLASH platform across five biomarkers, including pTau-217 and Aβ1-42, with limits of detection ranging from 0.0005 to 0.119 pg/mL. The system achieved an AUC of 0.839 for pTau-217 in a 101-participant cohort.
The details
The platform functions as a solid-phase proximity ligation assay, which allows for the detection of low-abundance proteins in the blood. Because it utilizes standard benchtop qPCR hardware, the method avoids the requirement for specialized, expensive, or centralized lab machines. The technology also supports the use of dried plasma spots, eliminating the need for cold-chain storage during transport.
Timeline
The findings were published on October 7, 2026.
Health Landscape
The push for simple blood tests marks a significant departure from relying solely on PET scans or CSF testing for Alzheimer's detection. This study highlights the latest technological hurdle being cleared in the broader effort to standardize blood-based biomarkers for Alzheimer's disease.
While this test represents a technical advancement in lab efficiency, it is not yet available for clinical use in your doctor's office. If you have concerns about memory or cognitive changes, keep following up with your physician about established diagnostic pathways and existing tests.
The takeaway
This new platform successfully uses standard hardware to identify Alzheimer's biomarkers at high sensitivity. When discussing cognitive health with your physician, focus on current, clinically validated screening options rather than preliminary diagnostic technologies.
Further reading
Learn more about the latest innovations in Alzheimer’s diagnostic research and screening tools.
Source note: This article includes information reported by Nature.
Live Poll
Should medical research focus on simplifying diagnostic tools for use in standard local labs?
